Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of Revenues and Accounts Receivables By Major Customers

The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Net revenues
Cephalon, Inc. (Teva) - See Revenue Recognition	67	%	77	%	78	%	72	%
SymBio Pharmaceuticals Limited	20	%	—	%	7	%	—	%
Other	13	%	23	%	15	%	28	%
	100	%	100	%	100	%	100	%



	September 30,		December 31,
	2017		2016
Accounts receivable
Cephalon, Inc. (Teva)	64	%	74	%
SymBio Pharmaceuticals Limited	18	%	—	%
Other	18	%	26	%
	100	%	100	%

Schedule of Dilutive and Anti-Dilutive Common Shares Equivalents Outstanding

The anti-dilutive common shares equivalents outstanding at the three and nine months ended September 30, 2017 and 2016 were as follows:



	Three Months Ended September 30,		Nine Months Ended September 30,
	2017	2016	2017	2016
Options	1,671,570	1,387,997	1,580,277	1,375,351
Total	1,671,570	1,387,997	1,580,277	1,375,351

Computation for Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the computation for basic and diluted net income per share for the three and nine months ended September 30, 2017 and 2016:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Numerator
Numerator for basic and diluted earnings per share-net income	$	15,431	$	11,952	$	42,858	$	24,152
Denominator
Basic weighted average common shares outstanding	15,047,917		15,570,740		15,174,426		15,614,328
Dilutive effect of stock options	716,443		879,442		840,625		886,839
Diluted weighted average common shares outstanding	15,764,360		16,450,182		16,015,051		16,501,167
Basic net income per share
Basic net income per share	$	1.03	$	0.77	$	2.82	$	1.55
Diluted net income per share
Diluted net income per share	$	0.98	$	0.73	$	2.68	$	1.46